Life Sciences

McKesson Invests $2.5B to Acquire Majority Stake in Flo...

McKesson has planned to enhance its oncology platform with a significant investm...

UCB Offloads Neurology and Allergy Meds in China for Ne...

It appears that restructuring is the trend for many big pharmaceutical companies...

Germany to Provide 100,000 Mpox Vaccine Doses to Combat...

Germany has provided 100,000 doses of the Mpox vaccine from its armed forces to ...

Pathalys Raises $105 Million in Series B to Prepare Ren...

Kidney disease biotech Pathalys Pharma has raised $105 million in a Series B fun...

Eli Lilly’s Weight Loss Drug Significantly Reduces Diab...

Eli Lilly’s weight loss drug, tirzepatide, has shown a 94% reduction in the inci...

Ascendis Receives a Grudging FDA Approval for Yorvipath...

Ascendis Pharma should be in a good position to launch its hormone replacement t...

Pfizer Releases ABRYSVO for RSV: Top-Line Results in Im...

Pfizer reported top-line interim safety and immunogenicity outcomes from Substud...

US FDA Rejects Lykos’ MDMA-Based PTSD Therapy

Lykos Therapeutics said that the U.S. Food and Drug Administration (FDA) has rej...

FDA Approves Ascendis’ Yorvipath for the Treatment of H...

Following its approval earlier this week and the scheduled withdrawal of Takeda’...

Voranigo Receives FDA Clearance as a Brain Tumor Inhibitor

Servier has enriched its portfolio of IDH-targeted drugs for next year thanks to...

Novo Nordisk Says Goodbye to GLP-1/GIP MASH Prospect

Novo Nordisk has decided to discontinue the development of a medication candidat...

Elon Musk Announces Neuralink’s Second Brain-Computer C...

Neuralink, founded by Elon Musk, revealed that it has placed its device in the s...

Vertex & CRISPR’s Casgevy Given the Green Light by NICE

Vertex and CRISPR Therapeutics are making headway on the difficult path to assur...

CVC Capital to pay $925 Million to Mallinckrodt for sal...

American-based specialty pharmaceutical company Mallinckrodt has undertaken the ...

Agios Fails to Reach Primary Objective in Pediatric Study

In spite of the fact that it failed to meet the primary goal in a pediatric rese...

Alpha Cognition’s ALPHA-1062 Becomes the Second Oral FD...

The FDA approved Vancouver-based Alpha Cognition’s ALPHA-1062, also known as Zun...